title: Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
abstract: OBJECTIVE
  Young adults with type 1 diabetes mellitus (T1DM) have increased glomerular filtration rate (GFR), which may mediate progressive renal disease and microalbuminuria. This may be secondary to low concentrations of insulin-like growth factor (IGF)-I and GH hypersecretion. We tested the hypothesis that restoration of circulating IGF-I concentrations in young adults with T1DM might suppress GH secretion, GFR and urinary albumin excretion.
  
  
  METHODS
  In a randomized double blind crossover study six young adults with T1DM (three men, 19-24 years) received 7 days treatment with rhIGF-I/insulin-like growth factor binding protein (IGFBP)-3 complex (SomatoKine) 0.4 mg/kg/day and placebo. Subjects underwent overnight insulin infusion for euglycaemia, followed by determination of GFR and albumin excretion rate.
  
  
  RESULTS
  Following IGF-I/IGFBP-3 complex, overnight insulin requirements (0.15 vs placebo 0.21 mU/kg/min, P < 0.04), plasma insulin (77 vs placebo 152 pmol/l, P < 0.01) and mean overnight GH (2.6 vs placebo 4.8 mU/l, P < 0.04) fell. IGF-I (492 vs placebo 218 ng/ml, P < 0.01) and IGFBP-3 (4.5 vs placebo 3.9 microg/ml, P < 0.05) increased. GFR did not change (145.5 (23.9) ml/min/1.73 m(2) post-IGF-I/IGFBP-3 complex vs 152.2 (19.8) post placebo). Albumin excretion rate did not change 9.5 (5.5-16.6)mg/24 h pre- vs 11.5 (9.9-20.2) post-IGF-I/IGFBP-3 complex and 10.7 (8.1-21.2) pre- vs 11.5 (8.7-29.9) post placebo. Plasma creatinine levels were lower following IGF-I/IGFBP-3 complex (mean +/- SD, 56.2 +/- 16.8 micromol/l) vs placebo (61.5, 45.0, P < 0.02).
  
  
  CONCLUSIONS
  Seven days treatment with IGF-I/IGFBP-3 complex enhanced overnight insulin sensitivity and reduced GH levels, but there was no effect on glomerular hyperfiltration or albumin excretion rates.
authors.affiliation: University of Cambridge, Department of Paediatrics, Cambridge, UK.
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Williams
authors.forename: Kevin
authors.initials: K
authors.lastname: Yuen
authors.forename: Debbie
authors.initials: D
authors.lastname: White
authors.forename: Beth
authors.initials: B
authors.lastname: Mallard
authors.forename: R Neil
authors.initials: RN
authors.lastname: Dalton
authors.forename: Carlo L
authors.initials: CL
authors.lastname: Acerini
authors.forename: David B
authors.initials: DB
authors.lastname: Dunger
mesh_terms: D000328:Adult; D000419:Albuminuria / Q000188:drug therapy / Q000209:etiology; D000704:Analysis of Variance; D017024:Chemotherapy, Adjuvant; D003404:Creatinine / Q000097:blood; D018592:Cross-Over Studies; D003864:Depression, Chemical; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000627:therapeutic use*; D008297:Male
chemical_list: D007328:Insulin; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D003404:Creatinine